Axion BioSystems, a leading life sciences tools company focused on cutting-edge live-cell bioelectronic assay and imaging systems, announces the acquisition of the intellectual property and assets of CytoTronics, Inc. The purchase brings novel high-density (HD) electrode array technology developed at Harvard University to Axion’s growing product suite and strengthens Axion’s ability to provide researchers with the most advanced tools for disease research and drug discovery.

Xendee Corporation, provider of the leading design and operation platform for distributed energy and microgrid systems, announced today the results of a new market survey executed by Energy Changemakers and Renewable Energy World that highlights how distributed energy and microgrid projects might be evolving in 2026 following federal policy changes and ongoing utility challenges.

Niron Magnetics and FaitalPRO announced the development of new professional audio loudspeakers featuring breakthrough Iron Nitride permanent magnets. These next-generation loudspeakers, which deliver strong acoustic performance while eliminating rare-earth dependencies, will be showcased at leading audio and audiovisual industry trade shows NAMM 2026 and ISE 2026.

NTx Bio, a leader in next-generation biomanufacturing technologies, today announced that Joan Haab, Ph.D., has been appointed as CEO by the Company Board of Directors. Dr. Haab previously served as Chief Operating Officer, and succeeds Jamie Coffin, Ph.D., who stepped down as CEO to focus on personal matters.

Niron Magnetics, a leading manufacturer of high-performance, rare-earth-free permanent magnets, today announced a collaboration with MATTER, India’s next-generation electric mobility technology company. Through this collaboration, MATTER will explore integrating Iron Nitride magnet technology and Variable Flux Motor (VFM) designs from Niron Magnetics into its high-performance electric motorbike products, strengthening its electric vehicle (EV) motor platforms.

InterVenn Biosciences, a precision diagnostics company advancing liquid biopsy with glycoproteomics, and Aranscia, a global provider of award-winning clinical workflow and diagnostic technology solutions, today announced a partnership where Aranscia technical and laboratory resources will help to facilitate clinical workflows and expand the availability of InterVenn’s flagship GlycoKnow™ Ovarian cancer diagnostic test.